Recent News

Web icon Corona Update

1 June 2020   H.E.L Group continues to respond to the fast-changing situation that the Covid-19 pandemic presents. Our primary concern…

Find out more
Mert Sahin_3

GE Healthcare Commercial Executive brings a breadth of experience in scientific instrumentation and global markets to drive North American presence Borehamwood,…

Find out more
H.E.L Group appoints Kevin O’Donovan as Chair Appointment brings significant Board and commercial experience to deliver sustainable company growth Borehamwood, UK, 07 April 2020: H.E.L Group (H.E.L), a global developer and manufacturer of innovative laboratory tools for process optimization, safety and scale-up, today announced the appointment of Kevin O’Donovan as Chair of the H.E.L Board of Directors. Kevin takes over from interim Chair, Jon Andrew, and will guide the Company to deliver sustainable growth while continuing to help customers solve complex scientific challenges. Kevin is a Business Angel and has built up a portfolio of investments in the life sciences over the last 20 years, sitting on a number of Boards as Chair or Non-Executive Director. Several of these companies have been successfully sold, with listings on Ofex and AIM. Previously, Kevin founded the molecular biology instrumentation company, Hybaid, and directed its growth from concept to trade sale for £12 million. Here his expertise lay in export, and he successfully implemented a global network of 40 companies. Kevin has an MBA which he obtained from the UK’s Kingston Business School. The announcement of the new Chair follows a number of recent leadership team appointments and builds on the Company’s strong growth initiatives and focus on strengthening production and service support.

Appointment brings significant Board and commercial experience to deliver sustainable company growth Borehamwood, UK, 07 April 2020: H.E.L Group (H.E.L), a…

Find out more